Healthcare

This report examines the venture capital (VC) trends in the health tech sector across the US and North America (2025–2030), focusing on valuations, investment signals, and emerging market opportunities. The health tech VC market is expected to grow from $8.3B in 2025 to $22.4B by 2030 (CAGR 21%). Key drivers include increased demand for telehealth, digital health platforms, AI-driven diagnostics, and personalized medicine. Strategic investments are shifting towards AI, patient data management, and healthcare infrastructure, with AI-led innovation making up 36% of total investments by 2030. By 2030, the health tech market will see more diversified portfolios, with fintech integration and mental health platforms receiving growing attention from investors.

This research examines Antimicrobial Stewardship Programs (ASPs) in healthcare systems from 2025 to 2030, focusing on cost avoidance and prescriber behavior modification. It evaluates how data-driven strategies and clinical decision support systems are reshaping the way antibiotics are prescribed, improving patient outcomes, and reducing the risk of antibiotic resistance. The report quantifies the economic impact, potential for prescriber compliance, and cost savings resulting from ASP integration. Insights are aimed at hospitals, healthcare systems, and policymakers implementing stewardship models to control costs and improve treatment accuracy.

Between 2025 and 2030, UK and EU neurotech-pharma collaborations transform depression care through AI-assisted compound screening, brain-computer drug delivery, and closed-loop neuromodulation. Market value for hybrid pharmacological-neurotechnology solutions rises from €3.1B to €9.4B (CAGR 24%). About 47% of trials combine neuromodulation with targeted molecules. Approval timelines shorten 22%, while efficacy uplift averages +18% HAM-D improvement versus mono-therapy. Venture funding exceeds €4.7B, primarily in the UK, Netherlands, and Germany. Commercial potential centers on measurable outcomes and digital-biomarker integration.

This report analyzes the hospital-at-home expansion in North America (2025–2030), focusing on reimbursement models and technology infrastructure needs. The market for hospital-at-home services is expected to grow from $12.6B in 2025 to $50.4B by 2030 (CAGR 32.1%). Key drivers include the rising demand for home-based healthcare, cost savings, and the integration of remote monitoring and telemedicine technologies. By 2030, technology infrastructure and reimbursement models will be central to ensuring widespread adoption, with Medicare and private insurers increasing coverage for home healthcare services.

Between 2025 and 2030, precision nutrition for metabolic disorders expands rapidly in North America, with market size increasing from $3.5B to $9.8B (CAGR 22.4%). AI-driven nutrigenomics services grow 3×, while reimbursement frameworks shift from 10% → 45% coverage of personalized nutrition plans. Despite this, payer reimbursement remains a challenge, especially for food-based interventions. Coverage for genomic testing and dietetic interventions improves, but cost-per-coverage remains high, creating a need for innovative value-based pricing models.

This report quantifies blockchain-enabled pharmaceutical traceability across Saudi Arabia and the Middle East (2025–2030), focusing on anti-counterfeiting outcomes, compliance, and ROI. We model end-to-end serialization (GTIN/SGTIN/aggregations), mobile verification at point of dispense, and cold-chain integrity via IoT oracles. Benchmarks include counterfeit incidence reduction, recall cycle times, scan events per pack, dispenser adoption, and payback periods. Findings show blockchain networks deliver measurable risk reduction, operational savings, and revenue protection, enabling ministries, MAHs, wholesalers, and pharmacies to meet regulatory mandates while improving public trust.

This report evaluates ATMP manufacturing scalability and cost-reduction strategies across the US and Europe (2025–2030). We quantify capacity build-out for cell, gene, and tissue therapies, model COGS reductions from closed-system automation, digital QMS, and lean cold-chain logistics, and estimate release-cycle time and failure-rate improvements. We also benchmark CapEx/Opex trajectories, labor productivity, and batch yields, plus bottlenecks in materials, analytics, and QA. Findings guide biopharma, CDMOs, payers, and regulators on where to invest to achieve scale, reliability, and lower price-per-patient.

Between 2025 and 2030, the U.S. healthcare ecosystem undergoes accelerated digital modernization inspired by NHS-scale interoperability frameworks. Health IT investments rise from $29B to $68B (CAGR 18%), with interoperability compliance improving from 51% to 87% across hospitals. Patient data exchange volumes triple, yet cybersecurity incidents grow +41% before stabilizing post-zero-trust adoption. FHIR and HL7 API integration reach 78% of systems, while encrypted data-lake adoption lowers breach impact costs −32%. Regulatory focus shifts toward verifiable audit trails and patient-controlled consent frameworks.

The report explores the rising impact of behavioral economics (BE) tools in clinical trial design, driving significant improvements in patient adherence, retention, and data completeness especially in North America. By 2030, BE engagement solutions help lift adherence by 22 percentage points, retention by 17 points, and reduce dropouts by 30%, directly boosting trial success rates and lowering per-participant costs. Integrated software platforms and services now deliver targeted nudges, incentives, and social prompts, with the market set to grow from $1.1B to $3.2B, as BE becomes a portfolio standard among large sponsors, biotechs, and academic groups.

Between 2025 and 2030, the market for Value-Based Insurance Design (VBID) for chronic conditions in North America grows from $7.8B to $25.6B (CAGR 27.3%). Provider-payer collaboration models become the driving force for reducing costs and improving patient outcomes in chronic disease management. These models incentivize healthcare providers to offer high-value care through risk-sharing agreements and outcome-based reimbursement, reducing the total cost of care. By 2030, 45% of chronic disease treatments in the U.S. and 30% in Canada will be governed by value-based payment structures, improving both patient access and healthcare efficiency.